Auven Therapeutics

Auven Therapeutics is a private equity company focused on the healthcare industry.

Auven Therapeutics is a private equity company focused on the healthcare industry. The Company’s strategy is to acquire controlling ownership in promising therapeutic products or platforms. The value of these therapeutic assets is then significantly enhanced by global development programs prior to selling them as clinically and commercially validated products to established pharmaceutical companies. Auven Therapeutics has built a diversified portfolio of biologic and small molecule therapeutic candidates for a wide range of therapeutic indications. The Company’s existing pipeline addresses critical unmet medical needs in cancer, ophthalmic conditions, women’s health and orphan diseases. It has ownership of or a controlling interest in the therapeutic assets of ADC Therapeutics, Spirogen, Resolvyx and Kiacta, and a minority investment in Kolltan and Sprout Pharmaceuticals. Founded in 2007 by industry veterans Stephen Evans-Freke and Dr. Peter B. Corr, Auven Therapeutics Management L.L.L.P. is an investment advisor with its principal place of business in the US Virgin Islands. It manages Auven Therapeutics Holdings L.P., a private equity fund, which has its registered office and principal place of business in the British Virgin Islands. Auven Therapeutics Development, the operating company of Auven Therapeutics Holdings L.P. manages drug development from its bases in Lausanne, Switzerland, New York, USA and Hamilton, Bermuda. Auven Therapeutics is an investment advisor with its principal place of business in the US Virgin Islands. It manages Auven Therapeutics Holdings L.P., a private equity fund, which has its registered office and principal place of business in the British Virgin Islands. Auven Therapeutics Development, the operating company of Auven Therapeutics Management L.L.L.P. Holdings L.P. manages drug development from its bases in Lausanne, Switzerland, New York, USA and Hamilton, Bermuda.